FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Amid escalating U.S.-China trade tensions, top Chinese drug research firms like WuXi AppTec and WuXi Biologics (HK:2269) are adjusting operations to mitigate supply chain risks. These companies are stockpiling U.S. supplies, sourcing alternatives, and considering local testing options to maintain continuity in pharmaceutical development.
China’s biotech sector, a key player in global drug R&D for companies like Pfizer (NYSE:PFE) and AstraZeneca (NASDAQ:AZN), traditionally relies on U.S. imports such as reagents and clinical samples. However, recent tariff hikes and fears of restricted access are forcing firms to pause or reconsider new projects. Some companies, including Innovent Biologics and BeOne Medicines, are now exploring options to test U.S. clinical samples domestically rather than shipping them to China, which may significantly raise costs.
According to industry sources, WuXi AppTec and its biotech clients have already swapped U.S.-made reagents for non-U.S. alternatives due to rising tariffs. Meanwhile, WuXi Biologics reportedly placed unusually large orders with U.S. suppliers in April as a hedge against future trade policy shifts.
JS Biosciences, a Chinese culture media maker, has received inquiries from at least 17 clients since April to stockpile local raw materials. Delays in importing critical components—such as culture media from Fujifilm’s U.S. unit—have already caused Chinese firms to withdraw from certain international contracts.
Though U.S. and Chinese officials have signaled progress toward easing restrictions, uncertainties remain. Industry leaders like NeuExcell Therapeutics’ Chen Gong express growing concern about the unpredictable nature of future tariffs and how it may impact clinical trials and biotech investment.
With over $1.4 billion in U.S. diagnostic and laboratory reagents exported to China in 2024, the stakes remain high for both countries’ pharmaceutical industries.
